Advertisement

Topics

Boehringer Ingelheim and Dicerna in NASH Pact

06:27 EST 10 Nov 2017 | CHEManager

Germany’s Boehringer Ingelheim is partnering US company Dicerna Pharmaceuticals to develop new RNAi therapeutics for liver diseases. The research collaboration and license agreement will initially focus on the discovery and development of novel GalXC RNAi therapeutics for non-alcoholic steatohepatitis (NASH), a chronic liver disease for which there is currently no approved treatment.

Original Article: Boehringer Ingelheim and Dicerna in NASH Pact

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim and Dicerna in NASH Pact"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...